AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer

At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, randomised, phase 3 clinical trial that was designed to evaluate bevacizumab combined with chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel or topotecan) for patients with platinum-resistant recurrent ovarian cancer.